Article, News
Prescient to advance PTX-100 to phase II for refractory T-cell lymphomas
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study of PTX-100 in patients with advanced malignancies. The study’s focus…
Article, News
Prescient Reveals PTX-100 Phase 1b Study Results in T-Cell Lymphoma
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study of PTX-100 in patients with advanced malignancies. The study’s focus…
Article, News
Phase 1b study of Prescient Therapeutics’ (ASX: PTX) PTX-100 shows excellent safety and promising efficacy in TCL patients
Prescient Therapeutics Limited (ASX: PTX) has shared encouraging PTX-100 Phase 1b study results. The findings were showcased at the annual meeting of the American Society of Hematology (ASH) in…
Article, News
Prescient Therapeutics (ASX: PTX) receives R&D Tax Rebate of $2.4M
In the latest announcement, clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) revealed the receipt of AU$2.4 million as R&D Tax Incentive rebate for the…
Article, News
Encouraging outcomes from Prescient Therapeutics’ (ASX: PTX) clinical-stage assets light up last quarter
Encouraging outcomes from Prescient Therapeutics’ (ASX: PTX) clinical-stage assets light up last quarter
Article, News
MoneyTalks: Prescient set for ‘big pay day’; Aerometrex to grab ‘blue ocean’ AI opportunity
Pitt Street Research has sent us its thesis on biotech stock, Prescient Therapeutics (ASX:PTX), with a valuation range of 11.6c (bear case) to 16.3c per share (bull case)….
Article, News
New research asserts that Prescient is deeply undervalued
Pitt Street Research has released an equity valuation report on clinical stage oncology company Prescient Therapeutics (ASX: PTX) that outlines a prosperous and swift path…
Article, News
Fight against cancer an enduring investment motivation in September quarter despite markets
Cancer remains one of the most pressing public health challenges worldwide, affecting millions of lives and compounding economic burdens along the way. The companies dedicated…
Article, News
New T-Cell Lymphoma therapy coming soon
Prescient Therapeutics is a Melbourne-based drug developer focused on cancer, with several platforms and products in its portfolio. Prescient Therapeutics’ lead compound is a small…
Article, News
Prescient Therapeutics to participate in prestigious conference; abstract online now
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has had its abstract for PTX-100 published on the American Society of Hematology (ASH) website ahead of the company’s presentation at…